- Home
- OABI vs CHRS Comparison
OABI vs CHRS Comparison
Compare OABI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OABI | CHRS |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | 114 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.4M | 291.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | OABI | CHRS |
|---|---|---|
| Price | $1.70 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.67 | $5.51 |
| AVG Volume (30 Days) | 272.5K | ★ 1.2M |
| Earning Date | 03-04-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | N/A |
| Revenue This Year | $52.42 | $73.08 |
| Revenue Next Year | $64.69 | $30.94 |
| P/E Ratio | ★ N/A | $1.07 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $0.72 |
| 52 Week High | $2.49 | $2.62 |
Technical Indicators
Market Signals| Indicator | OABI | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 49.67 |
| Support Level | $1.51 | $1.55 |
| Resistance Level | $1.75 | $1.75 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 5.13 | 38.54 |
Price Performance
Historical ComparisonAbout OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.